EAM
BCYC

Eventide Asset Management’s Bicycle Therapeutics BCYC Stock Holding History

Eventide Asset Management’s Portfolio BCYC Stock Details BCYC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-853,800
Closed -$25.3M – 152
2022
Q4 		$25.3M Hold
853,800
– – 0.5% 66
2022
Q3 		$19.9M Hold
853,800
– – 0.39% 75
2022
Q2 		$14.3M Sell
853,800
-409,671
-32% -$8.64M 0.31% 83
2022
Q1 		$55.4M Hold
1,263,471
– – 0.87% 41
2021
Q4 		$76.9M Buy
1,263,471
+100,000
+9% +$5.52M 0.98% 36
2021
Q3 		$48.4M Hold
1,163,471
– – 0.64% 51
2021
Q2 		$35.3M Buy
1,163,471
+751,633
+183% +$22.7M 0.47% 65
2021
Q1 		$12.3M Buy
+411,838
New +$10.6M 0.18% 110

Other funds holding BCYC

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Eventide Asset Management's BCYC Position: Q1 2023 in Review

Eventide Asset Management sold out of Bicycle Therapeutics (BCYC) in Q1 2023, closing a stake of 853,800 shares — an estimated $25.3M sold.

Eventide Asset Management first reported a position in BCYC in Q1 2021 and held it in 8 quarters. The position peaked at $76.9M in Q4 2021. 89 funds tracked by Wall St. Rank hold BCYC as of Q1 2023.

  • Eventide Asset Management reported no remaining Bicycle Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Eventide Asset Management sold 853,800 Bicycle Therapeutics shares in Q1 2023, an estimated $25.3M.
  • Eventide Asset Management first reported a position in Bicycle Therapeutics in Q1 2021 and held it in 8 quarters.
  • Eventide Asset Management's Bicycle Therapeutics position peaked at $76.9M in Q4 2021.
  • 89 funds tracked by Wall St. Rank held Bicycle Therapeutics as of Q1 2023.

Based on Eventide Asset Management's 13F filing for Q1 2023, filed 15 May 2023.